U.S. Markets closed

Tesaro, Inc. (TSRO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
149.11-4.08 (-2.66%)
At close: 4:00PM EDT
People also watch
CLVSKITEPBYIPTLAAGIO
  • Its like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • BCDA and XBIO are two other stocks that have a lot of potential.
  • Ipse timor timeri Solum habemus.http://dataunion.tistory.com/8374

    TESARO Inc NASDAQ $TSRO Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • After earning season, M&A talks between citi bank and big pharma start again. I heard from my adviser. Did anyone hear anything yet?
  • Very volatile stock . This stock is all over the place during the day because it takes more than just a collaboration for Europe approval to keep the momentum going . You need an approval .
  • "TSRO icharts pointing to 98."
    I believe that was your I.Q.
    nt
  • Revenues revised up. See you in green AM .
  • down after hrz
  • a short candidats?
  • TSRO icharts pointing to 98.
  • I think buyout of clvs
  • see you at 100
  • Buyout coming, GILD about to pull the trigger.
  • I bet bo of clvs happens instead
  • Hello fellow investors, anyone know when TSRO earnings report is and if they plan on announcing some prescription numbers? Thank you in advance.
  • Technicals are showing great signs of upside potential. Target : 187.48 at 9trading.
  • If TSRO treats 5000 patients on average would equate to 500 million plus in sales taking 100k as the average annual cost to a patient. As the label gets expanded and or depending upon success of treatment this could easily become billion dollar drug for TSRO. I think the only way the company maintains this valuation is on a buyout.
  • 129 is 200 day moving average here
  • oversold here, watch for big rebound
  • hoo whoo $$$